AZD5305: Clinical Trials

6 trials of AZD5305, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 recruiting. 6 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 3, Recruiting 3
Phase 15Active not recruiting 3, Recruiting 2

Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
AZD9750, AZD5305 - Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca62026-01-272026-10-02
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2RecruitingSWOG Cancer Research Network9002025-11-062026-03-30
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma
Phase 1 / Phase 2RecruitingAstraZeneca6222023-06-052026-10-05
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca1742022-06-022026-08-26
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma
Phase 1 / Phase 2RecruitingAstraZeneca4602021-10-182026-10-13
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca7022020-11-122026-09-21

Conditions studied

Endometrial Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Biliary Tract Neoplasms (1)  ·  Bulbo-Spinal Atrophy, X-Linked (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)  ·  Stomach Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

AstraZeneca (5)  ·  SWOG Cancer Research Network (1)

Countries

United States (6)  ·  Australia (5)  ·  United Kingdom (5)  ·  Japan (4)  ·  Canada (3)  ·  China (3)  ·  Italy (3)  ·  South Korea (3)  ·  Spain (3)  ·  Hungary (2)  ·  Poland (2)  ·  Taiwan (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Germany (1)

Top investigators

Anne C Chiang (1)  ·  Funda Meric-Bernstam, MD (1)  ·  Timothy Yap (1)

Results publications

PMID 35929986, PMID 39392424

NIH funding

2023 (1), U10CA180888 (1)